References
- Thomas ED. Bone marrow transplantation: a review. Semin Hematol 1999;36(Suppl 7):95–103.
- Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, . Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462–5.
- Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, . Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185–91.
- Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238–41.
- Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, . Long-term restoration of immunity against Epstein- Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551–5.
- Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004;4:595–602.
- Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005;175:7046–52.
- Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294–305.
- Melenhorst JJ, Solomon SR, Shenoy A, Hensel NF, McCoy JP Jr, Keyvanfar K, . Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J Immunother 2006;29:436–43; discussion 365–6.
- Foster AE, Leen AM, Lee T, Okamura T, Lu A, Vera J, . Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother 2007;30:506–16.
- Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, . Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008;112:1876–85.
- Sato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, . Impact of culture medium on the expansion of T cells for immunotherapy. Cytotherapy 2009;11:936–46.
- Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, . Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy 2009;11:912–22.
- Powell DJ Jr, Brennan AL, Zheng Z, Huynh H, Cotte J, Levine BL. Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy 2009;11:923–35.